Previous close | 94.44 |
Open | 92.34 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 89.56 - 94.66 |
52-week range | 77.26 - 245.26 |
Volume | |
Avg. volume | 489,981 |
Market cap | 23.615B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 95.76 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.29 (0.33%) |
Ex-dividend date | 15 Dec 2021 |
1y target est | N/A |
The Board of Directors of Ambu A/S has appointed Britt Meelby Jensen as new Chief Executive Officer (CEO). Britt Meelby Jensen has served as board member of Ambu since 2019, a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will leave Ambu after three years and support the new CEO in the transition as needed. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on
For Q2, Ambu posted organic revenue growth of 8% with reported growth of 12%. The macroeconomic headwinds with inflation and continued congestion of the global supply chain are further increasing our costs of production and distribution. We also expect a return of elective procedures to above 2019 levels, but with lower benefit from pent-up demand due to hospital labour shortages. With 70% of our revenue coming from elective procedures, we adjust our financial outlook downward to organic growth
Ambu A/S hereby announces in reference to Section 30 of the Danish Capital Markets Act that on April 26, 2022, pursuant to Section 38(1) of the Danish Capital Markets Act, Ambu has received a major shareholder notification from Bank of America Corporation bringing Bank of America Corporation above 5% of share capital or voting rights in Ambu A/S. See attached standard form for notification of major holdings from Danish FSA. CONTACTS Investors Michael Højgaard, CFO, miho@ambu.com / +45 4030 4349N